Results 121 to 130 of about 5,478,695 (241)

Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing [PDF]

, 2019
CAR-NK cells may represent a valuable tool, complementary to CAR-T cells, in adoptive immunotherapy of leukemia and solid tumors. However, gene transfer to human NK cells is a challenging task, particularly with non-virus-based techniques.
Ingegnere T., Quintarelli C., Mariotti F. R., Cantoni C., Moretta L., Tumino N., Pelosi A., Besi F., Locatelli F., Vacca P., De Angelis B.   +10 more
core   +1 more source

CAR-NK cell therapy: promise and challenges in solid tumors

Frontiers in Immunology
Over the past few years, cellular immunotherapy has emerged as a promising treatment for certain hematologic cancers, with various CAR-T therapies now widely used in clinical settings. However, challenges related to the production of autologous cell products and the management of CAR-T cell toxicity highlight the need for new cell ...
Sahar Balkhi, Gaia Zuccolotto, Anna Di Spirito, Antonio Rosato, Antonio Rosato, Lorenzo Mortara   +5 more
openaire   +3 more sources

Chronic conditions associated with paediatric onset inflammatory bowel diseases: A population‐based study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective Several conditions are associated with inflammatory bowel disease (IBD), including immune‐mediated inflammatory diseases (IMIDs), extraintestinal manifestations (EIMs), and psychiatric disorders. This study aimed to describe at population‐level the comorbidities and their relative burden in paediatric‐onset IBD (pIBD).
Nicolas Richard, Ariane Leroyer, Hélène Sarter, Claire Dupont, Dominique Turck, Valérie Bertrand, Pauline Wils, Corinne Gower‐Rousseau, Guillaume Savoye, Nathalie Guillon, Delphine Ley, Mathurin Fumery, EPIMAD Study Group, R. Al Hameedi, M. Al Khatib, S. Al Turk, E. Agoute, J.M. Andre, M. Antonietti, A. Aouakli, A. Armand, L. Armengol‐Debeir, I. Aroichane, F. Assi, J.P. Aubet, E. Auxenfants, A. Avram, F. Ayafi‐Ramelot, K. Azzouzi, D. Bankovski, B. Barbry, N. Bardoux, P. Baron, A. Baudet, P. Bayart, B. Bazin, A. Bebahani, J.P. Becqwort, S. Bellati, V. Benet, H. Benali, C. Benard, C. Benguigui, E. Ben Soussan, A. Bental, I. Berkelmans, J. Bernet, K. Bernou, C. Bernou‐Dron, P. Bertot, N. Bertiaux‐Vandaële, V. Bertrand, E. Billoud, N. Biron, B. Bismuth, M. Bleuet, F. Blondel, V. Blondin, M. Bobula, P. Bohon, V. Bondjemah, E. Boniface, D. Bonkovski, P. Bonnière, E. Bonvarlet, P. Bonvarlet, A. Boruchowicz, R. Bostvironnois, M. Boualit, A. Bouazza, B. Bouche, C. Boudaillez, C. Bourgeaux, M. Bourgeois, A. Bourguet, A. Bourienne, H. Boutaleb, A. Bouthors, J. Branche, G. Bray, F. Brazier, P. Breban, M. Bridenne, H. Brihier, L. Bril, V. Brung‐Lefebvre, P. Bulois, P. Burgiere, J. Butel, J.Y. Canva, V. Canva‐Delcambre, J.P. Capron, F. Cardot, S. Carette, P. Carpentier, E. Cartier, J.F. Cassar, M. Cassagnou, J.F. Castex, P. Catala, S. Cattan, S. Catteau, B. Caujolle, G. Cayron, C. Chandelier, M. Chantre, J. Charles, T. Charneau, M. Chavance‐Thelu, A. Cheny, D. Chirita, A. Choteau, J.F. Claerbout, P.Y. Clergue, H. Coevoet, G. Cohen, R. Collet, M. Colin, J.F. Colombel, S. Coopman, L. Cordiez, J. Corvisart, A. Cortot, F. Couttenier, J.F. Crinquette, V. Crombe, I. Dadamessi, H. Daoudi, V. Dapvril, T. Davion, S. Dautreme, J. Debas, S. Decoster, N. Degrave, F. Dehont, C. Delatre, R. Delcenserie, D. Delesalle, O. Delette, T. Delgrange, L. Delhoustal, J.S. Delmotte, S. Demmane, G. Deregnaucourt, P. Descombes, J.P. Desechalliers, P. Desmet, P. Desreumaux, G. Desseaux, P. Desurmont, A. Devienne, E. Devouge, M. Devred, A. Devroux, A. Dewailly, S. Dharancy, A. Di Fiore, D. Djedir, R. Djedir, W. Doleh, Ml. Dreher‐Duwat, R. Dubois, C. Duburque, P. Ducatillon, J. Duclay, B. Ducrocq, F. Ducrot, P. Ducrotte, A. Dufilho, C. Duhamel, D. Dujardin, C. Dumant‐Forest, J.L. Dupas, F. Dupont, Y. Duranton, A. Duriez, N. Duveau, K. El Achkar, M. El Farisi, C. Elie, M.C. Elie‐Legrand, A. Elkhaki, M. Eoche, E. Essmaeel, D. Evrard, J.P. Evrard, A. Fatome, B. Filoche, L. Finet, M. Flahaut, C. Flamme, D. Foissey, P. Fournier, Mc. Foutrein‐ Comes, P. Foutrein, D. Fremond, T. Frere, M. Fumery, P. Gallais, C. Gamblin, S. Ganga, R. Gerard, G. Geslin, Y. Gheyssens, N. Ghossini, S. Ghrib, T Gilbert, B. Gillet, D. Godart, P. Godard, J.M. Godchaux, R. Godchaux, G. Goegebeur, O. Goria, F. Gottrand, P. Gower, B. Grandmaison, M. Groux, C. Guedon, L. Guerbeau, M. Gueroult‐Dero, J.F. Guillard, L. Guillem, F. Guillemot, D. Guimberd, B. Haddouche, S. Hakim, D. Hanon, V. Hautefeuille, P. Heckestweiller, G. Hecquet, J.P. Hedde, H. Hellal, P.E. Henneresse, B. Heyman, M. Heraud, S. Herve, P. Hochain, L. Houssin‐Bailly, P. Houcke, B. Huguenin, S. Iobagiu, S. Istanboli, A. Ivanovic, I. Iwanicki‐Caron, E. Janicki, M. Jarry, J. Jeu, Jp. Joly, C. Jonas, A. Jouvenet, F. Katherin, A. Kerleveo, A. Khachfe, A. Kiriakos, J. Kiriakos, O. Klein, M. Kohut, R. Kornhauser, D. Koutsomanis, Je. Laberenne, E. Lacotte, G. Laffineur, M. Lagarde, A. Lalanne, A. Lalieu, P. Lannoy, J. Lapchin, M. Laprand, D. Laude, R. Leblanc, P. Lecieux, S. Lecleire, N. Leclerc, C. Le Couteulx, J. Ledent, J. Lefebvre, P. Lefiliatre, C. Le Goffic, C. Legrand, A. Le Grix, P. Lelong, B. Leluyer, C. Lemaitre, C. Lenaerts, G. Lepeut, L. Lepileur, A. Leplat, E. Lepoutre‐Dujardin, H. Leroi, M.Y. Leroy, P. Le Roy, B. Lesage, Jp. Lesage, X. Lesage, J. Lesage, I. Lescanne‐Darchis, J. Lescut, D. Lescut, B. Leurent, P. Levy, M. Lhermie, L. Libier, A. Lion, B. Lisambert, I. Loge, F. Loire, J. Loreau, S. Louf, A. Louvet, L. Lubret, M. Luciani, D. Lucidarme, J. Lugand, O. Macaigne, D. Maetz, D. Maillard, H. Mancheron, O. Manolache, Ab. Marks‐Brunel, C. Marre, R. Marti, F. Martin, G. Martin, E. Marzloff, P. Mathurin, J. Mauillon, V. Maunoury, J.L. Maupas, Ma. Medam Djomo, C. Mechior, Z. Melki, B. Mesnard, P. Metayer, L. Methari, B. Meurisse, F. Meurisse, L. Michaud, X. Mirmaran, P. Modaine, A. Monthe, L. Morel, P.E. Mortier, E. Moulin, O. Mouterde, N. Mozziconaci, J. Mudry, M. Nachury, Md. Ngo, E. N'Guyen Khac, B. Notteghem, V. Ollevier, A. Ostyn, A. Ouraghi, B. Oussadou, D. Ouvry, B. Paillot, C. Painchart, N. Panien‐Claudot, C. Paoletti, A. Papazian, B. Parent, B. Pariente, Jc. Paris, P. Patrier, T. Paupard, B. Pauwels, M. Pauwels, E. Penninck, R. Petit, M. Piat, S. Piotte, C. Plane, B. Plouvier, E. Pollet, P. Pommelet, D. Pop, C. Pordes, G. Pouchain, P. Prades, A. Prevost, Jc. Prevost, G. Quartier, B. Quesnel, A.M. Queuniet, Jf. Quinton, A. Rabache, P. Rabelle, G. Raclot, S. Ratajczyk, D. Rault, V. Razemon, N. Reix, T. Renaut‐Vantroys, M. Revillion, G. Riachi, C. Richez, P. Robinson, J. Rodriguez, J. Roger, J.M. Roux, A. Rudelli, A. Saber, G. Savoye, P. Schlossberg, D. Sefrioui, M. Segrestin, D. Seguy, C. Seminur, M. Serin, A. Seryer, F. Sevenet, N. Shekh, J. Silvie, V. Simon, C. Spyckerelle, N. Talbodec, N. Tavernier, H. Tchandeu, A. Techy, J.L. Thelu, A. Thevenin, H. Thiebault, J. Thomas, J.M. Thorel, C. Thuillier, G. Tielman, M. Tode, J. Toisin, J. Tonnel, Jy. Touchais, P. Toumelin, Y. Touze, J.L. Tranvouez, C. Triplet, N. Triki, D. Turck, S. Uhlen, E. Vaillant, C. Valmage, D. Vanco, N. Vandaele‐Bertiaux, H. Vandamme, E. Vanderbecq, E. Vander Eecken, P. Vandermolen, P. Vandevenne, L. Vandeville, A. Vandewalle, C. Vandewalle, P. Vaneslander, J.P. Vanhoove, A. Vanrenterghem, C. Vanveuren, P. Varlet, I. Vasies, G. Verbiese, J. Verlynde, G. Vernier‐Massouille, P. Vermelle, C. Verne, P. Vezilier‐Cocq, B. Vigneron, M. Vincendet, J. Viot, Y.M. Voiment, A. Wacrenier, L. Waeghemaecker, J.Y. Wallez, M. Wantiez, F. Wartel, J. Weber, J.L. Willocquet, N. Wizla, E. Wolschies, O. Zaharia, S. Zaoui, A. Zalar, B. Zaouri, A. Zellweger, C. Ziade   +480 more
wiley   +1 more source

eVLP-mediated CREM editing enhances cytotoxicity of bicistronic IL-15-armored CD19/BCMA dual-target CAR-NK cells

Frontiers in Immunology
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells represent a promising platform for cancer immunotherapy; however, optimization of CAR architecture and additional engineering strategies remain necessary to improve their functional ...
Fengqin Shang, Guanlie Li, Shiting Gong, Lijiao Zhao, Bingyu Niu, Hanyi Chen, Yuchen Fu, Lijun Zhao, Jianxun Wang, Yuanyuan Shi   +9 more
doaj   +1 more source

Fine-tuning signal strength in CD5 CAR-NK cells for targeted T cell cancer therapy [PDF]

IntroductionT cell hematological malignancies are aggressive blood cancers that remain challenging despite various treatments. Current chimeric antigen receptor (CAR)-T and natural killer (NK) therapies show potential but struggle with nonselective ...
Myeongjin Choi, Mi-lang Kyun, Sunyoung Lee, Seona Jo, Soo Yun Lee, Ji Hyun Kim, Kyoung-Sik Moon, Seo Yule Jeong, Yu Bin Lee, Yu Jung Kim, Sora Park, Seok Min Kim, Yoonji Kim, Tae-Don Kim   +13 more
core   +1 more source

CAR NK cell therapy for solid tumors: potential and challenges

Antibody Therapeutics
Abstract CAR-T cell therapy has shown promise but is constrained by side effects and limited efficacy in treating solid tumors. Compared to CAR-T cells, CAR natural killer (NK) cells derived from multiple versatile sources exhibit more favorable safety profiles and possess the unique ability to refine cytotoxic activity, serve as off ...
Yanlin Yu, Mitchell Ho
openaire   +3 more sources

Organoid Coculture Models for Cancer Research and Immunotherapy

Med Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang, Huihui Yang, Guangxin Li, Guobang Liu, Zhulan Chen, Wenzhi Tian, Meiyang Huang, Xiaoling Liu, Yongsheng Zhao, Dong Chen   +9 more
wiley   +1 more source

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation

Journal for ImmunoTherapy of Cancer
Background The antitumor activity of natural killer (NK) cells can be enhanced by specific targeting with therapeutic antibodies that trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or by genetic engineering to express chimeric antigen ...
Torsten Tonn, Hans Klingemann, Winfried S Wels, Jiri Eitler, Natalie Wotschel, Laurent Boissel, Michael Bachmann, Wiebke Rackwitz, Venugopal Gudipati, Nivedha Murali Shankar, Anastasia Sidorenkova, Johannes B Huppa, Paola Ortiz-Montero, Corinna Opitz, Stephan R Künzel, Susanne Michen, Achim Temme, Liliana Rodrigues Loureiro, Anja Feldmann   +18 more
doaj   +1 more source

Precision sniper for solid tumors: CAR-NK cell therapy

Cancer Immunology, Immunotherapy
Abstract Chimeric antigen receptor (CAR) represents a novel targeted therapy that uses genetic engineering to modify effector cells for precise tumor cell targeting. Chimeric antigen receptor-T (CAR-T) cell immunotherapy, which employs T cells as effectors, has demonstrated significant efficacy in treating hematologic malignancies.
Li, Sisi, Jing, Jiajie, Chen, Yueming, Chi, Enjie, Wang, Bingyan, Xie, Ziwen, Yang, Wenya, Shen, Hongqiang, Pan, Jianping   +8 more
openaire   +2 more sources

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source